GSK suspends dosing in Crohn's disease treatment trial

08/26/2013 | Reuters

GlaxoSmithKline said adverse events increased at a new higher dosage in a trial of vercirnon, an experimental treatment licensed from ChemoCentryx. The findings prompted GSK to suspend new patient recruitment and dosing pending further analysis in the Crohn's disease study. "The results from the SHIELD-1 study are clearly disappointing but we are committed to further explore the data to determine the way forward to help patients with this chronic debilitating gastrointestinal disease," a GSK official said.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Chicago, IL
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC